Roger Stupp

Research interests

Publications

• RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults

  Journal of Clinical Oncology · 2023 · https://doi.org/10.1200/jco.23.01059

• Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial

  Nature Medicine · 2023 · https://doi.org/10.1038/s41591-023-02347-y

• cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas

  Acta Neuropathologica · 2020 · https://doi.org/10.1007/s00401-020-02127-9

• MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges

  Neuro-Oncology · 2018 · https://doi.org/10.1093/neuonc/noy132

• cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

  Acta Neuropathologica · 2018 · https://doi.org/10.1007/s00401-018-1913-0

• Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2017.5082

• IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma

  Clinical Cancer Research · 2018 · https://doi.org/10.1158/1078-0432.ccr-17-3573

• European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30194-8

• Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial

  The Lancet Oncology · 2017 · https://doi.org/10.1016/s1470-2045(17)30517-x

• Lomustine and Bevacizumab in Progressive Glioblastoma

  New England Journal of Medicine · 2017 · https://doi.org/10.1056/nejmoa1707358

• Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma

  JAMA · 2017 · https://doi.org/10.1001/jama.2017.18718

• Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

  The Lancet · 2017 · https://doi.org/10.1016/s0140-6736(17)31442-3

• Glioma

  Nature Reviews Disease Primers · 2015 · 10.1038/nrdp.2015.17

• Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma

  JAMA · 2015 · https://doi.org/10.1001/jama.2015.16669

• High-grade glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2014 · 10.1093/annonc/mdu050

• Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70379-1

• EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70011-7

• MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

  Acta Neuropathologica · 2012 · https://doi.org/10.1007/s00401-012-1016-2

• NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality

  European Journal of Cancer · 2012 · https://doi.org/10.1016/j.ejca.2012.04.011

• Current concepts and management of glioblastoma

  Annals of Neurology · 2011 · https://doi.org/10.1002/ana.22425

• Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

  Journal of Clinical Oncology · 2010 · 10.1200/jco.2009.26.3541

• Phase 3 Randomized Trial on Larynx Preservation Comparing Sequential vs Alternating Chemotherapy and Radiotherapy

  JNCI Journal of the National Cancer Institute · 2009 · https://doi.org/10.1093/jnci/djn460

• MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

  Nature Reviews Neurology · 2009 · 10.1038/nrneurol.2009.197

• Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

  The Lancet Oncology · 2009 · 10.1016/s1470-2045(09)70025-7

• Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.15.7164

• Correlation of O 6 -Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.11.5964

• Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker*

  Brain Pathology · 2008 · https://doi.org/10.1111/j.1750-3639.2008.00153.x

• Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043330

• MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma

  New England Journal of Medicine · 2005 · 10.1056/nejmoa043331

Current projects

No projects listed.